Hematologic Malignancy
Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
CI-CAN-00005967PTCLExplore in graph →
Hematologic172 active trials13 approved drugs9 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00005967PTCLExplore in graph →
Clinical trials
786 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (129)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00014235 | Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies | completed | N/A | 160 | Fred Hutchinson Cancer CenterOTHER | 3 | Jan 21, 2020 | clinicaltrials |
| NCT00078858 | Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant | completed | Phase 1 / Phase 2 | 37 | Fred Hutchinson Cancer CenterOTHER |
| 3 |
| Jan 18, 2020 |
| clinicaltrials |
| NCT01110733 | Comprehensive Oncology Measures for Peripheral T-cell Lymphoma Treatment Registry(COMPLETE) | completed | — | 3,000 | Acrotech Biopharma Inc.INDUSTRY | 1 | Jan 13, 2020 | clinicaltrials |
| NCT00481871 | Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies | completed | Phase 1 / Phase 2 | 119 | Acrotech Biopharma Inc.INDUSTRY | 1 | Jan 7, 2020 | clinicaltrials |
| NCT00554827 | Study of Pralatrexate in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma | completed | Phase 1 | 55 | Acrotech Biopharma Inc.INDUSTRY | 1 | Jan 3, 2020 | clinicaltrials |
| NCT01839097 | Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL) | completed | Phase 1 | 23 | Acrotech Biopharma Inc.INDUSTRY | 1 | Jan 3, 2020 | clinicaltrials |
| NCT00003196 | Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma | completed | N/A | 63 | Fred Hutchinson Cancer CenterOTHER | 3 | Dec 27, 2019 | clinicaltrials |
| NCT00364923 | Study of Pralatrexate With Vitamin B12 and Folic Acid in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma(PROPEL) | completed | Phase 2 | 115 | Acrotech Biopharma Inc.INDUSTRY | 6 | Dec 19, 2019 | clinicaltrials |
| NCT01134341 | Pralatrexate and Bexarotene in Patients With Relapsed or Refractory Cutaneous T-cell Lymphoma | completed | Phase 1 | 34 | Acrotech Biopharma Inc.INDUSTRY | 2 | Dec 18, 2019 | clinicaltrials |
| NCT01326702 | Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors | completed | Phase 1 / Phase 2 | 43 | National Cancer Institute (NCI)NIH | 1 | Dec 16, 2019 | clinicaltrials |
| NCT02106650 | Phase II Study of Folotyn With Leucovorin to Prevent/Reduce Mucositis in Patients With Hematological Malignancies | completed | Phase 2 | 36 | Acrotech Biopharma Inc.INDUSTRY | 1 | Nov 20, 2019 | clinicaltrials |
| NCT02652715 | Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma | completed | N/A | 29 | Mayo ClinicOTHER | 1 | Nov 15, 2019 | clinicaltrials |
| NCT00856388 | Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders | completed | N/A | 62 | Roswell Park Cancer InstituteOTHER | 1 | Nov 13, 2019 | clinicaltrials |
| NCT01007448 | Study Evaluating Two Dose Levels of Targretin Capsules in Participants With Refractory Cutaneous T-Cell Lymphoma (CTCL) | completed | Phase 4 | 59 | Bausch Health Americas, Inc.INDUSTRY | 1 | Nov 12, 2019 | clinicaltrials |
| NCT00105001 | Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 210 | Fred Hutchinson Cancer CenterOTHER | 3 | Oct 30, 2019 | clinicaltrials |
| NCT00106431 | A Single Agent Phase II Study of Romidepsin (Depsipeptide, FK228) in the Treatment of Cutaneous T-cell Lymphoma (CTCL) | completed | Phase 2 | 102 | CelgeneINDUSTRY | 6 | Oct 30, 2019 | clinicaltrials |
| NCT01822886 | Phase II Study of Gemcitabine+Romidepsin in the Relapsed/Refractory Peripheral T-cell Lymphoma Patients(FIL_GEMRO) | completed | Phase 2 | 20 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Oct 14, 2019 | clinicaltrials |
| NCT03349333 | A Single Arm Study Evaluating the Efficacy and Safety of Pralatrexate in Subjects With Relapsed or Refractory PTCL | completed | Phase 3 | 85 | Mundipharma (China) Pharmaceutical Co. LtdINDUSTRY | 1 | Oct 1, 2019 | clinicaltrials |
| NCT01529827 | Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 94 | Roswell Park Cancer InstituteOTHER | 1 | Sep 24, 2019 | clinicaltrials |
| NCT02243579 | Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome | completed | Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | Sep 20, 2019 | clinicaltrials |
| NCT00005799 | Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer | completed | N/A | 55 | Fred Hutchinson Cancer CenterOTHER | 2 | Sep 10, 2019 | clinicaltrials |
| NCT02822586 | TSEB and Brentuximab for Treatment of Mycosis Fungoides & Sezary Syndrome | completed | Phase 1 | 5 | Virginia Commonwealth UniversityOTHER | 1 | Aug 30, 2019 | clinicaltrials |
| NCT01676831 | Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL) | completed | Phase 1 / Phase 2 | 13 | Abramson Cancer Center at Penn MedicineOTHER | 1 | Aug 13, 2019 | clinicaltrials |
| NCT01839916 | Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 77 | University of ChicagoOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT03040206 | Risk Stratification of Nodal PTCL | completed | — | 405 | Chonbuk National University HospitalOTHER | 1 | Aug 7, 2019 | clinicaltrials |
| NCT02809573 | Clinical Trial of Chidamide Combined With CHOP in Peripheral T-cell Lymphoma Patients | completed | Phase 1 | 30 | Chipscreen Biosciences, Ltd.INDUSTRY | 1 | Jul 24, 2019 | clinicaltrials |
| NCT00697346 | Study of MLN8237 in Participants With Advanced Hematological Malignancies | completed | Phase 1 | 58 | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | May 31, 2019 | clinicaltrials |
| NCT01800838 | Silicon Phthalocyanine 4 and Photodynamic Therapy in Stage IA-IIA Cutaneous T-Cell Non-Hodgkin Lymphoma | completed | Phase 1 | 11 | Kevin Cooper MDOTHER | 1 | May 16, 2019 | clinicaltrials |
| NCT01897012 | Alisertib and Romidepsin in Treating Patients With Relapsed or Refractory B-Cell or T-Cell Lymphomas | completed | Phase 1 | 26 | National Cancer Institute (NCI)NIH | 1 | Jan 28, 2019 | clinicaltrials |
| NCT01093586 | Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies | completed | Phase 2 | 14 | Case Comprehensive Cancer CenterOTHER | 1 | Jan 23, 2019 | clinicaltrials |
| NCT01401530 | E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma | completed | Phase 1 | 13 | Eisai Co., Ltd.INDUSTRY | 1 | Nov 23, 2018 | clinicaltrials |
| NCT00038025 | A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies | completed | Phase 2 | 60 | M.D. Anderson Cancer CenterOTHER | 1 | Nov 16, 2018 | clinicaltrials |
| NCT00038376 | Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies | completed | Phase 2 | 56 | M.D. Anderson Cancer CenterOTHER | 1 | Oct 29, 2018 | clinicaltrials |
| NCT01590732 | Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma | completed | Phase 1 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 19, 2018 | clinicaltrials |
| NCT03226119 | MP Diagnostics HTLV Blot 2.4 Post-Market Clinical Study | completed | Phase 4 | 150 | MP Biomedicals, LLCINDUSTRY | 1 | Sep 13, 2018 | clinicaltrials |
| NCT01273766 | Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies | completed | Phase 2 | 16 | Wake Forest University Health SciencesOTHER | 1 | Sep 7, 2018 | clinicaltrials |
| NCT01686165 | Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHL | completed | Phase 2 | 5 | University of ArizonaOTHER | 1 | Aug 28, 2018 | clinicaltrials |
| NCT00136565 | Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma | completed | Phase 2 | 60 | Lymphoma Study AssociationOTHER | 2 | Aug 23, 2018 | clinicaltrials |
| NCT00221039 | Photopheresis as an Interventional Therapy for the Treatment of CTCL (Cutaneous T-Cell Lymphoma, Mycosis Fungoides) Stage 1A, 1B, 2A | completed | Phase 4 | 7 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 17, 2018 | clinicaltrials |
| NCT01482962 | Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma | completed | Phase 3 | 271 | Millennium Pharmaceuticals, Inc.INDUSTRY | 31 | Jul 31, 2018 | clinicaltrials |
| NCT01484015 | Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia | completed | Phase 1 | 70 | Wake Forest University Health SciencesOTHER | 1 | Jul 18, 2018 | clinicaltrials |
| NCT01053494 | Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer | completed | N/A | 80 | Wake Forest University Health SciencesOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT01129193 | AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma | completed | Phase 1 | 44 | Amir MortazaviOTHER | 1 | Jun 4, 2018 | clinicaltrials |
| NCT01724177 | A Phase 2 Study of Lenalidomide in Patients With Relapsed or Recurrent Adult T-cell Leukemia-lymphoma | completed | Phase 2 | 26 | CelgeneINDUSTRY | 1 | May 29, 2018 | clinicaltrials |
| NCT00961220 | O6-Benzylguanine and Topical Carmustine in Treating Patients With Early-Stage IA-IIA Cutaneous T-Cell Lymphoma | completed | Phase 1 / Phase 2 | 17 | National Cancer Institute (NCI)NIH | 1 | May 22, 2018 | clinicaltrials |
| NCT01567709 | Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma | completed | Phase 1 | 34 | National Cancer Institute (NCI)NIH | 1 | Apr 11, 2018 | clinicaltrials |
| NCT02142530 | Carfilzomib Plus Belinostat in Relapsed/Refractory NHL | completed | Phase 1 | 19 | Massachusetts General HospitalOTHER | 1 | Jan 25, 2018 | clinicaltrials |
| NCT02825147 | Pegaspargase and Methotrexate Based Regimens for Newly Diagnosed Extranodal NK/T Cell Lymphoma | completed | Phase 2 | 40 | Ruijin HospitalOTHER | 1 | Nov 14, 2017 | clinicaltrials |
| NCT02013362 | Phase I/II Clinical Study of Pralatrexate in Japanese Patients With Relapsed or Refractory Peripheral T-cell Lymphoma | completed | Phase 1 / Phase 2 | 25 | Mundipharma K.K.INDUSTRY | 1 | Nov 9, 2017 | clinicaltrials |
Data updated 23 days agoSource updated Jan 21, 2020source: clinicaltrials